All Stories

  1. Mast cell degranulation and histamine release during A/H5N1 influenza infection in influenza-sensitized mice
  2. Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines
  3. The prevalence of conjunctivitis in patients with novel coronavirus (COVID-19) and preventive measures
  4. Contribution of antibody-dependent enhancement to the pathogenesis of coronavirus infections
  5. Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice
  6. INDUCTION OF CROSS-REACTIVE ANTIBODIES IN MICE IMMUNIZED WITH CONSERVED LINEAR B-CELL EPITOPES DERIVED FROM INFLUENZA A VIRUS NEURAMINIDASE
  7. Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections
  8. Introductory Chapter: Human Adenoviruses
  9. Adenoviruses
  10. Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection
  11. Preparing Live Influenza Vaccines against Potential Pandemic Influenza Using Nonpathogenic Avian Influenza Viruses and Cold-Adapted Master Donor Strain
  12. Anti–Influenza Activity of Enterocin B In vitro and Protective Effect of Bacteriocinogenic Enterococcal Probiotic Strain on Influenza Infection in Mouse Model
  13. Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals
  14. Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides
  15. Baculovirus as a platform for the anchorage of hemagglutinin from influenza virus
  16. The crystal structure of an orthomyxovirus matrix protein reveals mechanisms for self-polymerization and membrane association
  17. Evaluation in Mouse Model of Combined Virus-bacterial Vaccine Based on Attenuated Influenza A(H7N3) Virus and the Group B Streptococcus Recombinant Polypeptides
  18. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers
  19. Live Attenuated Influenza H7N3 Vaccine is Safe, Immunogenic and Confers Protection in Animal Models
  20. Assessment of Human Immune Responses to H7 Avian Influenza Virus of Pandemic Potential: Results from a Placebo–Controlled, Randomized Double–Blind Phase I Study of Live Attenuated H7N3 Influenza Vaccine
  21. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza
  22. 6-sulfo sialyl Lewis X is the common receptor determinant recognized by H5, H6, H7 and H9 influenza viruses of terrestrial poultry
  23. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential
  24. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses
  25. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents